

RESEARCH PAPER

Spray-Drying as a Method for Microparticulate Controlled Release Systems Preparation: Advantages and Limits. I. Water-Soluble Drugs

Giovanni Filippo Palmieri,* Giulia Bonacucina,
Piera Di Martino, and Sante Martelli

*Università di Camerino, Dipartimento di Scienze Chimiche,
Via S. Agostino 1, 62032 Camerino (MC), Italy*

ABSTRACT

Spray-drying was used for the preparation of paracetamol/eudragit RS or RL or ethylcellulose microspheres to verify the possibility of their use in controlled-release solid-dosage forms formulation and try to determine advantages and limits of the technique of such use. Microspheres were first characterized by scanning electron microscopy, differential scanning calorimetry, x-ray diffractometry, and in vitro dissolution studies and then used for the preparation of tablets. During this step, the compressibility of the spray-dried powders was also evaluated. In vitro dissolution studies were performed also on the tablets and their release control was accessed. Although powders were unable to slow down drug release, tablets obtained from microsphere compression showed a good capability of controlling paracetamol release when eudragit RS or ethylcellulose was used, even at low polymer amounts.

KEY WORDS: Microspheres; Paracetamol; Spray-drying; Tablets.

INTRODUCTION

Spray-drying is a technique allowing the instantaneous drying of solutions, suspensions, or emulsions. Recently, the process received great attention in the field of

microparticles for the preparation of dried liposomes (1,2), amorphous drugs (3), mucoadhesive microspheres (4,5), drying of preformed microcapsules (6–8), gastroresistant microspheres (9–14), and controlled-release systems (15–31). Despite the great number of works carried out on

*To whom correspondence should be addressed.

controlled-release systems, the limits of the method, concerning the possibility of formulating an oral controlled-release system, have not been set yet. In fact, the success of this kind of formulation mostly depends on the equilibrium between the type of polymer used to retain the drug and the water solubility of the same drug. Thus, the authors tried to find out what drug solubility is suitable for the formulation of a microparticulate oral controlled-release system using the most known and effective water-insoluble polymers as eudragit RL and RS or ethylcellulose. In this work article, attention is given to drugs having an intermediate water solubility. For this reason, paracetamol (water solubility, 1:70 w/w) was chosen to prepare microspheres with eudragit RL or RS or ethylcellulose by the spray-drying method.

The obtained powders were then compressed to verify paracetamol release also from tablets and compare it with that obtained from tablets having the same composition but prepared by direct compression of drug and polymers powders.

MATERIALS AND METHODS

Microspheres Preparation

A certain amount of eudragit RS or RL (Röhm, Darmstadt, Germany) or ethylcellulose NF 50 (Aqualon) was first dissolved in the minimal quantity of ethanol 96% necessary to maintain the polymer in solution when diluted with water from 96 to 75%. This solution was diluted with water to obtain a 75% ethanol solution and then a certain amount of paracetamol (ACEF, Fiorenzuola D'Arda, Italy) was added to obtain the following w/w drug/polymer ratios: 1:2, 1:1, 2:1, 3:1, 4:1, 6:1, 9:1, and 19:1.

This final solutions were spray-dried with a Büchi B-191 minispray-dryer under the following conditions: feed rate, 15 mL/min; inlet temperature, 110°C; outlet temperature, 85°C; pressure 4 bar and throughput of drying air, 35 m³/hr. The collected powders were stored under vacuum in a dessiccator for 2 days and then analyzed.

Microspheres Analysis

A certain amount of all the different spray-dried powders were crushed in a mortar and assayed spectrophotometrically (Cary 1E UV-VIS, Varian) at 257 nm in distilled water ensure that no loss of drug or variation in the composition occurred during preparation. Scanning electron microscopy analysis was carried out with a Stereoscan 360 (Cambridge Instruments Limited, Cambridge, UK)

on all series of microspheres to obtain a visual image and evaluate their particle size, shape, and surface.

Differential scanning calorimetry was performed on the microspheres with a Perkin-Elmer Pyris 1 differential scanning calorimeter connected to a personal computer. Each sample (3 mg of powder in aluminium pans) was heated at a heating rate of 10°C/min between 100 and 200°C.

X-ray diffractograms of the prepared powders and of pure drug and polymers were taken with a Philips PW 1730 x-ray generator using CuK_α radiation and a goniometer camera.

Tablets Preparation

All the series of microspheres, prepared as described above, were compressed by an instrumented 10-station rotary press type Piccola (Ronchi, Cinisello Balsamo, Italy) to obtain 250 mg tablets of 8 Kp crushing strength (Erweka TBH30 hardness tester). Tablets, having the same composition and crushing strength of those described above but obtained by direct compression of drug and polymer powders could not be prepared because the physical mixtures of paracetamol and each of the polymers, in turn, were not compressible at all. The addition of other excipients such as the lubricant was spontaneously avoided to study the effect on the drug release characteristics only attributable to the structure and composition of the microspheres.

Dissolution Studies

The dissolution studies were performed in triplicate on all the different series of tablets and spray-dried powders with an Erweka DT6 dissolution test, using the paddle method at the rotation speed of 75 rpm (USP XXIII Apparatus 2). One tablet of each series was put into a vessel with 1000 mL of HCl 0.1N. At 10-min intervals, 3 mL of water was withdrawn, passed through a 0.45-μm membrane filter (Millipore), and assayed spectrophotometrically at 257 nm to measure the concentration of drug present in the solution. The initial volume of the vessel was maintained by adding 3 mL of HCl 0.1N after each sampling.

After 2 hr, the tablet was recovered and immediately put into 1000-mL phosphate buffer (pH 7). At 10 min-intervals, 3 mL of water were withdrawn, passed through a 0.45-μm membrane filter, and assayed spectrophotometrically at 257 nm for 6 hr. The initial volume of the vessel was maintained by adding 3 mL of phosphate buffer after each sampling.

RESULTS AND DISCUSSION

Microspheres Analysis

The UV analyses performed on the prepared powders show in all cases a 100% drug content according to the theoretical composition. Figures 1 and 2 show the SEM images of paracetamol/ethylcellulose 1:2 and 4:1 microspheres, respectively. Both types of microspheres have a similar mean diameter (25 to 30 μm) and are formed by clusters of smaller microparticles. The form of these smaller particles depends on the composition of the microspheres. They are not spherical when the amount of ethylcellulose exceeds that of drug (Fig. 1) and become gradually spherical as the quantity of paracetamol increases (Fig. 2).

Figures 3 and 4 show the SEM images of paracetamol/eudragit RS 1:2 and 4:1 microspheres, respectively. In this case, microspheres having a higher polymer amount are a little bigger (55- μm mean diameter) than those with more paracetamol (25- μm mean diameter), but both are formed by clusters of smaller particles. Unlike the ethylcellulose-containing microparticles, these smaller particles forming clusters are quite spherical, even at the 1:2 drug/polymer ratio.

Figures 5 and 6 show the SEM images of paracetamol/eudragit RL 1:2 and 4:1 microspheres, respectively. There

is a considerable difference between paracetamol/eudragit RS and paracetamol/eudragit RL 1:2 particles. In fact, these last particles are not spherical. Paracetamol/eudragit RL particles begin to resemble those containing eudragit RS when the amount of drug increases, because both the 4:1 particles are clusters of smaller microspheres. Figures 7 through 9 show the thermograms of paracetamol/ethylcellulose, paracetamol/eudragit RS, and paracetamol/eudragit RL microspheres, respectively, at different drug/polymer ratios. In all cases, solid solubility of the paracetamol in the polymers is less than 30% because a very flat and large drug-melting peak can be detected even in the drug/polymer 1:2 ratio. Figure 10 shows the values of the enthalpy of fusion of the peaks visible in Figures 7 through 9 reported against the percentage of paracetamol in the powder. In this way, the limit of solid solubility can be extrapolated as the intercept between the line, obtained from the experimental points, and the x -axis. The calculated limits are 30% for eudragit RS and RL and 17% for ethylcellulose. Thus, the two acrylic polymers are more effective to disperse monomolecularly the drug in their own solid matrix.

Figure 11 shows the x-ray diffractograms of the raw paracetamol and polymers powders compared with the spray-dried drug/polymer 1:2 powders. Peaks of paracetamol crystals are always present in all the 1:2 spray-dried powders, even if very reduced in intensity.




Figure 1. SEM image of paracetamol/ethylcellulose 1:2 microspheres.




Figure 2. SEM image of paracetamol/ethylcellulose 4:1 microspheres.




Figure 3. SEM image of paracetamol/eudragit RS 1:2 microspheres.



Figure 4. SEM image of paracetamol/eudragit RS 4:1 microspheres.




Figure 5. SEM image of paracetamol/eudragit RL 1:2 microspheres.




Figure 6. SEM image of paracetamol/eudragit RL 4:1 microspheres.

This result is in agreement with DSC data and confirms the presence of paracetamol crystals in the powders. The peaks of paracetamol increase in intensity as the amount of paracetamol in the spray-dried powders increases too (data not shown).

Compression Studies

The compressibility of paracetamol/ethylcellulose, paracetamol/eudragit RS, and paracetamol/eudragit RL

spray-dried powders is shown in Figures 12 through 14, respectively, where their crushing strength/compression force curves are reported.

Regardless of the type of polymer present in the microspheres, as the amount of polymer increases, the compaction properties are gradually improved too. The compressibility is still acceptable when the amount of drug present does not exceed 80%, except for the paracetamol/eudragit RL microspheres, which seem to be less compressible at a low polymer content. In fact, in this




Figure 7. DSC curves of paracetamol/ethylcellulose microspheres.




Figure 8. DSC curves of paracetamol/eudragit RS microspheres.




Figure 9. DSC curves of paracetamol/eudragit RL micro-break spheres.

case in which microparticles contain 50% of polymer, the crushing strength/compression force curve is similar to that obtained from microparticles containing only 20% of ethylcellulose or eudragit RS.

Another very interesting result is represented by the increased compaction abilities of the spray-dried powders in comparison with those of the corresponding physical mixtures, which turned out to be impossible to convert into tablets because of their very poor compaction properties. Moreover, the compaction ability of drug/eudragit RL 1:2 and drug/ethylcellulose 1:1 microspheres is very similar to that of Avicel, known to be a very compressible filler in tablets preparation. In addition, the drug/ethylcellulose 1:2 microspheres are even more compressible than Avicel.

This could depend on their morphological characteristics or on the variation of the physical structure of the solid




Figure 10. Paracetamol solid solubility in ethylcellulose, Eudragit RS, and RL.




Figure 11. X-ray diffractograms of the raw paracetamol and polymer powders compared with the spray-dried drug/polymer 1:2 powders.

spray-dried powders respecting a drug/polymer simple physical mixture or to both these two effects.

In any case, even if the spray-drying process often improves the compressibility of materials, the improvement level reached by the microspheres powders in comparison with the raw materials was quite unexpected. For this reason, this finding will be investigated further using more refined techniques such as F-D or Hekel plots.

Dissolution Studies

The reported values are the arithmetical mean of three measurements, and SD bars are omitted to avoid overlapping.

Dissolution profiles of microspheres are not shown because they are very similar to those of the pure drug, with no evidence of slow release. This is probably attributable to the porosity of the spray-dried particles, which are responsible for the fast water penetration inside microspheres. A very different result is achieved once the microspheres are converted into tablets. In fact, as shown in Figures 15 through 17, in which the release




Figure 12. Crushing strength/compression force curves of the paracetamol/ethylcellulose microspheres.




Figure 13. Crushing strength/compression force curves of the paracetamol/eudragit RS microspheres.




Figure 14. Crushing strength/compression force curves of the paracetamol/eudragit RL microspheres.




Figure 15. Release kinetics of tablets obtained from paracetamol/ethylcellulose microspheres.




Figure 16. Release kinetics of tablets obtained from paracetamol/eudragit RS microspheres.




Figure 17. Release kinetics of tablets obtained from paracetamol/eudragit RL microspheres.

kinetics of tablets obtained from drug/ethylcellulose or eudragit RS or eudragit RL microspheres are presented, the compression process sensibly slows down the drug release. This phenomenon depends on the strong reduction of particle porosity. Still, differences in the release kinetics can be found between tablets containing ethylcellulose or eudragit RS and those containing eudragit RL.

As one should expect, the latter is less effective in paracetamol-release rate slowing down because eudragit RL is more permeable and swellable in water than the other two polymers.

Besides, aside from the type of polymer present in the tablets, differences on drug-release rate are related to the amount of paracetamol contained in the tablets. As drug content increases, its release from tablet becomes faster.

Finally, if ethylcellulose or eudragit RS is used, the presence of just a small amount of polymer in the tablet is enough to guarantee drug-release control. In fact, the drug/polymer 9:1 and even 19:1 tablets are still able to retard drug release.

CONCLUSION

Microspheres paracetamol/polymer can be easily prepared by spray-drying. Even if they are not spherical, they are in most cases clusters of smaller and spherical microparticles, as shown by the scanning electron microscope.

Differential scanning calorimetry and x-ray diffractometry gave no evidence of eutectics or complexes formation between paracetamol and the polymers used. On the other hand, these two techniques showed the very good paracetamol solid solubility in the three polymers. The compaction abilities of the spray-dried microspheres are by far greater than the corresponding physical mixtures, which could not be transformed into tablets. Besides, microspheres containing 50% or more of eudragit RS or ethylcellulose possess compaction abilities similar or even better than those of Avicel.

In vitro dissolution studies pointed out the impossibility of formulating, by spray-drying, a microparticulate oral controlled-release system of a drug such as paracetamol having a 1:70, or similar, water solubility. Despite this result, very effective oral controlled-release systems can be obtained if the spray-dried microspheres are converted into tablets even when the content of polymer is low.

ACKNOWLEDGMENTS

The authors gratefully acknowledge the financial support of Italian MURST (40% Funds, national project *Technologie Farmaceutiche*).

REFERENCES

1. Kikuki, H.; Yamauchi, H.; Hirota, S. *Chem. Pharm. Bull.* **1991**, *39*, 1522–1527.
2. Payne, N.I.; Salmon, J.; Roger, J. U.S. US 4,830,858 **1989**; CA 111 P 102760a.
3. Corrigan, O.I.; Holohan, E.H.; Sabra, K. *Int. J. Pharm.* **1984**, *18*, 195–200.
4. Illum, L.; Jorgensen, H.; Bisgaard, H.; Krogsgaard, O.; Rossing, N. *Int. J. Pharm.* **1987**, *39*, 189–199.
5. Vidgren, P.; Vidgren, M.; Arppe, J.; Hakuli, T.; Laine, E.; Paronen, P. *Drug Dev. Ind. Pharm.* **1992**, *18*, 581–597.
6. Luzzi, L.A.; Zoglio, M.A.; Maulding, H.V. *J. Pharm. Sci.* **1970**, *59*, 338–341.
7. Palmieri, G.F.; Martelli, S.; Lauri, D.; Wehrle, P. *Drug Dev. Ind. Pharm.* **1996**, *22*, 951–957.
8. Palmieri, G.F.; Martelli, S.; Lauri, D.; Wehrle, P. *Drug Dev. Ind. Pharm.* **1999**, *25*, 399–407.
9. Takenaka, H.; Kawashima, Y.; Lin, S.Y. *J. Pharm. Sci.* **1980**, *69*, 1388–1392.
10. Takenaka, H.; Kawashima, Y.; Lin, S.Y. *J. Pharm. Sci.* **1981**, *70*, 1256–1260.
11. Takeuchi, H.; Handa, T.; Kawashima, Y. *Chem. Pharm. Bull.* **1987**, *35*, 3800–3806.
12. Lin, S.Y.; Kao, Y.H. *Pharm. Res.* **1991**, *8*, 919–924.
13. Senjovic, R.; Becirevic, M.; Rudic, J. *Pharmazie* **1990**, *45*, 749–751.
14. Giunchedi, P.; Torre, M.L.; Maggi, L.; Conti, B.; Conte, U. *Drug Dev. Ind. Pharm.* **1995**, *21*, 315–324.
15. Bodmeier, R.; Chen, H. *J. Pharm. Pharmacol.* **1988**, *40*, 754–757.
16. Takeuchi, H.; Handa, T.; Kawashima, Y. *Drug Dev. Ind. Pharm.* **1989**, *15*, 1999–2016.
17. Wan, L.S.C.; Heng, P.W.S.; Chia, C.G.H. *Int. J. Pharm.* **1991**, *77*, 183–191.
18. Forni, F.; Coppi, G.; Vandelli, M.A.; Camerini, R. *Chem. Pharm. Bull.* **1991**, *39*, 2091–2095.
19. Wan, L.S.C.; Heng, P.W.S.; Chia, C.G.H. *Drug Dev. Ind. Pharm.* **1992**, *18*, 997–1011.
20. Mathiowitz, E.; Bernstein, H.; Giannos, S.; Dor, P.; Turek, T.; Langer, R. *J. Appl. Polym. Sci.* **1992**, *45*, 125–134.
21. Mao, L.; Zhang, R. *Zhongguo Yiyao Gongye Zazhi.* **1993**, *24*, 394–394.
22. Palmieri, G.F.; Wehrle, P.; Stamm, A. *Drug Dev. Ind. Pharm.* **1994**, *20*, 2859–2879.
23. Pavanetto, F.; Genta, I.; Giunchedi, P.; Conti, B.; Conte, U. *J. Microencapsulation.* **1994**, *11*, 445–454.

24. Pavanetto, F.; Genta, I.; Giunchedi, P.; Conti, B. J. Microencapsulation. **1993**, *10*, 487–497.
25. Giunchedi, P.; Conti, B.; Maggi, L.; Conte, U. J. Microencapsulation. **1994**, *11*, 381–393.
26. Pavanetto, F.; Conti, B.; Giunchedi, P.; Genta, I.; Conte, U. Eur. J. Pharm. Biopharm. **1994**, *40*, 27–31.
27. Conte, U.; Giunchedi, P.; Maggi, L.; Torre, M.L. Eur. J. Pharm. Biopharm. **1994**, *40*, 203–208.
28. Wagenaar, B.W.; Muller, B.W. Biomaterials. **1994**, *15*, 49–54.
29. Conte, U.; Conti, B.; Giunchedi, P.; Maggi, L. Drug Dev. Ind. Pharm. **1994**, *20*, 235–258.
30. Conti, B.; Puglisi, G.; Ventura, C.A.; Giunchedi, P.; Conte, U.; Caruso, A.; Cutuli, V. STP Pharma Sci. **1994**, *4*, 269–274.
31. Wan, L.S.C.; Heng, P.W.S.; Liew, C.V. Int. J. Pharm. **1995**, *118*, 213–219.

Copyright of Drug Development & Industrial Pharmacy is the property of Taylor & Francis Ltd and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use.